Biology Reference
In-Depth Information
Galle J, Lehmann-Bodem C, Hubner U, Heinloth A, Wanner C (2000) CyA and OxLDL
cause endothelial dysfunction in isolated arteries through endothelin-mediated stimulation of
O2- formation. Nephrol Dial Transplant 15:339-346
Girolami B, Bernardi E, Prins MH, Ten Cate JW, Hettiarachchi R, Prandoni P, Girolami A, Buller
HR (1999) Treatment of intermittent claudication with physical training, smoking cessation,
pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med 159:337-345
Goto S (2005) Cilostazol: potential mechanism of action for antithrombotic effects accompanied
by a low rate of bleeding. Atheroscler Suppl 6:3-11
Greenhaff PL, Campbell-O'Sullivan SP, Constantin-Teodosiu D, Poucher SM, Roberts PA,
Timmons JA (2004) Metabolic inertia in contracting skeletal muscle: a novel approach
for pharmacological intervention in peripheral vascular disease. Br J Clin Pharmacol 57:
237-243
Gudmundsdottir IJ, McRobbie SJ, Robinson SD, Newby DE, Megson IL (2005) Sildenafil
potentiates nitric oxide mediated inhibition of human platelet aggregation. Biochem Biophys
Res Commun 337:382-385
Hambleton R, Krall J, Tikishvili E, Honeggar M, Ahmad F, Manganiello VC, Movsesian MA (2005)
Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic
activity in subcellular fractions of human myocardium. J Biol Chem 280:39168-39174
Hankey GJ, Norman PE, Eikelboom JW (2006) Medical treatment of peripheral arterial disease.
JAMA 295:547-553
Hashimoto A, Miyakoda G, Hirose Y, Mori T (2006) Activation of endothelial nitric oxide
synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-
dependent mechanism. Atherosclerosis 189:350-357
Hiatt WR (2001) Medical treatment of peripheral arterial disease and claudication. N Engl J Med
344:1608-1621
Hiatt WR (2004) Carnitine and peripheral arterial disease. Ann NY Acad Sci 1033:92-98
Hiatt WR, Regensteiner JG, Creager MA, Hirsch AT, Cooke JP, Olin JW, Gorbunov GN, Isner J,
Lukjanov YV, Tsitsiashvili MS, Zabelskaya TF, Amato A (2001) Propionyl-L-carnitine
improves exercise performance and functional status in patients with claudication. Am J
Med 110:616-622
Hiatt WR, Money SR, Brass EP (2008) Long-term safety of cilostazol in patients with peripheral
artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg
47:330-336
Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy
WRC, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ,
White J, White RA (2006) ACC/AHA 2005 practice guidelines for the management of patients
with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic).
Circulation 113:e463-e465
Honda F, Imai H, Ishikawa M, Kubota C, Shimizu T, Fukunaga M, Saito N (2006) Cilostazol
attenuates gray and white matter damage in a rodent model of focal cerebral ischemia. Stroke
37:223-228
Igawa T, Tani T, Chijiwa T, Shiragiku T, Shimidzu S, Kawamura K, Kato S, Unemi F, Kimura Y
(1990) Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial
cells. Thromb Res 57:617-623
Ikeda U, Ikeda M, Kano S, Kanbe T, Shimada K (1996) Effect of cilostazol, a cAMP phosphodi-
esterase inhibitor, on nitric oxide production by vascular smooth muscle cells. Eur J Pharmacol
314:197-202
Ikenoya M, Doi T, Miura T, Sawanobori K, Nishio M, Hidaka H (2007) Investigation of binding
proteins for anti-platelet agent K-134 by Drug-Western method. Biochem Biophys Res Com-
mun 353:1111-1114
Ikewaki K, Mochizuki K, Iwasaki M, Nishide R, Mochizuki S, Tada N (2002) Cilostazol, a potent
phosphodiesterase type III
inhibitor, selectively increases antiatherogenic high-density
